

## DAFTAR PUSTAKA

1. Moch H, Humprey PA, Ulbright TM, Reuter VE. Acinar Adenocarcinoma Prostate. In : WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4<sup>th</sup> ed. IARC; 2016; 136-62.
2. Beg S, Francesca K, Robinson BD. Pathology of Prostat Cancer. In : (Robinson BD, Mosquera JM, Ro JY, Divatia M) Precision Molecular Pathology of Prostate Cancer. New York: Springer. 2018; 49-69
3. Bostwick DG, Cheng L, Meiers I. Neoplasma of The Prostat. In: (Bostwick DG, Cheng L) Urologic Surgical Pathology. 3<sup>th</sup> ed. Philadelphia: Elsevier Saunder; 2015; 409-31
4. American Cancer Society. Global Cancer Facts and Figure. 3<sup>rd</sup> edition. Atlanta : American Cancer Society. 2015.
5. Bashir NM. Epidemiology of Prostate Cancer. Asian Pasific Journal of Cancer Prevention. 2015; 16(13): 5137-41.
6. Moul JW. Population Cancer for Prostate Cancer and Early Detection. In : (Mydlo JH, Godec CJ) Prostate Cancer Science and Clinical. 2<sup>nd</sup> ed. Amsterdam: Elsevier. 2016; 8-17.
7. Chen R, Ren S, Yiu MK, Fai NC, Cheng WS, *et al.* Prostate Cancer in Asia: A Collaborative Report. Asian Journal of Urology. 2014; 1: 15-29.
8. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia. Kanker di Indonesia tahun 2014 : Data Histopatologik. Jakarta : Direktorat Jendral Pelayanan Medik Kementerian Kesehatan RI, Yayasan Kanker Indonesia. 2018
9. Zhong J, Rao J. Epidemiological and Molecular Features of Prostate Cancer in Asian Men Living in Asian Countries : Implication in Screen and Management. Clinics in Oncology-Prostate Cancer. 2016; 1-7
10. Amin MB, Tickoo SK. Prostate Gland and Seminal Vesicle. In: Diagnostic Pathology Genitourinary. 2<sup>nd</sup> ed. Philadelphia: Elsevier. 2016; 536-14.
11. Offerman A, Hohenstainer S, Kuemper C, Idel JK, Schneider F, *et al.* Prognostic Value of New Prostate Cancer International Society of Urological Pathology Grade Group. Frontier in Medicine. 2017; 4; 1-7.
12. Shah RB, Zhou M. Review Article : Recent Advances in Prostate Cancer Pathology : Gleason Grading and Beyond. Pathology International. 2016; 66 (5): 260-72.
13. Cheng L, Mazzuchelli R, Jones TD, Beltran AL, Montironi R. The Pathology of Prostate Cancer. In : (Su LM) Early Diagnosis and Cancer Treatment : Prostate Cancer. Philadelphia: Elsevier; 2010; 45-83.
14. Meng Y, Liao YB, Xu P, Wei WR, Wang J. Perineural Invasion is an Independent Predictor of Biochemical Recurrent of Prostate Cancer After Local Treatment : a Meta-analysis. Int J Clin Exp Med. 2015; 8(8): 13267-74.

15. Yang R, Cao K, Han T, Zhang FY, Zhang GT, Xu LF, *et al.* Perineural Invasion Status, Gleason Score, and Number of Positive Cores in Biopsy Pathology are Predictors of Positive Surgical Margin Following Laparoscopic Radical Prostatectomy. *Asian Journal of Andrology*. 2017; 468-72.
16. Lubig S, Thiesler T, Muller Stefan, Vorreuther R, Leipner N, Kristiansen G. Quantitative Perineural Invasion is a Prognostic Marker in Prostate Cancer. *Pathology*. 2018;1-7.
17. Lee TJ, Lee S, Yun CJ, Jeon BJ, Kim JM *et al.* Prediction of Perineural Invasion and Its Prognostic Value in Patients With Prostate Cancer. *Korean Journal of Urology*. 2010; 51(11): 745-51.
18. Cozzi G, Rocco BM, Grasco A, Rosso M, Rahman DA, *et al.* Perineural Invasion as a Predictor of Extraprostatic Extension of Prostate Cancer : A Systematic Review and Meta-analysis. *Scandinavian Journal of Urology*. 2013; 47: 443-48.
19. Celik S, Bozkurt O, Demir O, Gurboga O, Tuna B, *et al.* Effect of Perineural Invasion in Prostate Needle Biopsy on Tumor Grade and Biochemical Recurrence Rates after Radical Prostatectomy. *Kaohsiung Journal of Medical Science*. 2018;34:385-90.
20. Zhang LJ, Wu B, Zha ZL, Qu W, Hu Z, Yuan J. Perineural Invasion as an Independent Predictor of Biochemical Recurrence in Prostate Cancer Following Radical Prostatectomy or Radiotherapy : a Systematic Review and Meta-analysis. *BMC Urology*. 2018;18:5.
21. Saeter T, Bogaard M, Vlatkovic L, Waaler G, Servoll E, *et al.* The Relationship Between Perineural Invasion, Tumor Grade, Reactive Stroma, and Prostate Cancer-Specific Mortality : A Clinicopathology Study on Population-Based Cohort. *The Prostate*. 2015; 76(2): 207-14.
22. Atti LD. Prognostic Significance of Perineural Invasion In Patients Who Underwent Radical Prostatectomy for Localized Prostate. *Journal of Balkan Union of Oncology*. 2016; 21(5): 1219-23.
23. Komite Penanggulangan Kanker Nasional. Panduan Penatalaksanaan Kanker prostat. Kementerian Kesehatan Republik Indonesia. 2015.
24. Penticuff JC, Kyprianou N. Pathophysiology of Castration-Resistant Prostate Cancer. In: (Balaji KC) *Managing Metastatic Prostate Cancer in Your Urological Oncology Practice*. New York: Springer; 2016; 5-20.
25. Lonergan PE, Tindall DJ. Androgen Receptor Signalling in Prostate Cancer Development and Progression. *Journal of Carcinogenesis*. 2011; 10 (20).
26. Saraon P, Drabovich AP, Jarvi KA, Diamandis EP. Mechanism of Androgen-Independent Prostate Cancer. *Journal of The International Federation of Clinical Chemistry and Laboratory Medicine*. 2014; 25(1): 42-53
27. Traish AM, Morgantaler A. Epidermal Growth Factor Receptor Expression Escape Androgen Regulation in prostate cancer : a Potential Molecular Switch for Tumor Growth. *British Journal of Cancer*. 2009; 101(2): 1949-56.

28. Wang Z. Androgene Responsive Genes in Prostate Cancer: Regulation, Function, and Clinical Application. Newyork: Springer. 2013.
29. Bollu LR, Ren J, Chen J, Gao G, Weihua Z. Epidermal Growth Factor Receptor. In : (You Z) Prostate Cancer Cells. Nova Science. 2013; 147-53.
30. Huang Y, Chang Y. Epidermal Growth Factor Receptor (EGFR) Phosphorylation, Signalling and Trafficking. In: (Spiess PE) Prostate Cancer. Prostate Cancer-From Bench to Bedside. Intech Open Science. 2011.
31. Hashmi AA, Hashmi SK, Irfan M, Asif M, Nisar L, Naeem M, *et al.* Prognostic Utility of Epidermal Growth Factor Receptor (EGFR) Expression in Prostatic Acinar Adenocarcinoma. Applied Cancer Research. 2019; 39(2)
32. Weber CD, Tille JC, Combescue C, Egger JF, Laouti M, Hammad K, *et al.* The Prognostic Value of Expression of HIF1 $\alpha$ , EGFR, and VEGF-A in localized Prostate Cancer for intermediate and high-risk Patient Treated with Radiation Therapy with or without Androgene Deprivation Therapy. Radiation Oncology. 2012;7:66
33. Okegawa T, Itaya N, Hara H, Tambo M, Nutahara K. Epidermal Growth Factor Receptor Status in Circulating Tumor Cell as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy. International Journal of Molecular Science. 2016; 17(12).
34. Lorenzo G, Tortora F, Armiento , Francesco P, Rosa DG, Staibano S, *et al.* Expression of Epidermal Growth Factor Receptor Correlate with Disease Relapse and Progression to Androgene-Independence in Human Prostate Cancer. American Association for Cancer Research. 2002; 8: 3438-44.
35. Mofid B , Nadoushan J, Rakhsha A, Mirzaei HR, Zeinali. Epidermal Growth Factor Receptor Gene in Prostate Cancer after Radical Prostatectomy. Iranian Journal of Cancer Prevention. 2010; 3(4):174-77
36. Baek KH, Hong ME, Jung YY, Lee CH, Lee TJ, Park ES. *et al.* Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic *In Situ* Hybridization. Cancer Research and Treatment. 2012;44(1).
37. Mandel A, Larsson P, Sarwar M, Semenas J, Khaja AS, Persson JS. The Interplay Between AR, EGF receptor and MMP-9 Signalling Pathways in Invasive Prostate Cancer. Molecular Medicine. 2018; 24(34).
38. Zhou M, Galluzi CM. Neoplastic Disease of The Prostate. In : (Zhou M, Galluzi CM) Genitourinary Pathology. 2<sup>nd</sup> ed. Philadephia: Elsevier; 2015. 78-146.
39. Park YW, Turner KO, Zhai QJ. Normal Prostate Histology : Diagnostically Significant Features. In : (Ro JY, Zhai QJ, Shen SS, Ayala AG) Advances in Surgical Pathology Prostate Cancer. Philadelphia: Wolters Kluwer. 2012; 69-80.



40. Epstein JI, Lotal TL. The lower Urinary Tract and Male Genital System. In (Kumar V, Abbas AK, Aster JC) Robbin and Cotran Pathologic Basis of Disease. 9<sup>th</sup> ed. Philadelphia: Elsevier. 2014. pp 959-990.
41. Shah RB, Zhou M. Prostate Biopsy and Interpretation : an Illustrated Guide. Newyork; Springer. 2012 .
42. Zinger DL, Parwani AV. Prostate Pathology. Demos Medical : Newyork. 2015
43. Alexandrescu E, Georgescu D, Multescu R, Geavlete B, Geavlete P, *et al.* Inflammation and Prostate Cancer-Correlation Between the degree of Inflammation and the Gleason Score. Revista Romana de Urologie. 2014; 13.
44. Schulman CC, Irani J, Morote J, Schalken JA, Montorsi F, Chlosta PL. Testosterone Measurement in Patient with Prostate Cancer. European Association of Urology. 2010; 65-74.
45. McKenney. Prostat and Vesicles Seminalis. In (Goldblum JM, Lamps LW, McKenney JK, Myers JL) Rosai and Ackerman's Surgical Pathology. Philadelphia: Elsevier; 2018; 1097-1134.
46. Zhou M, Netto G, Epstein J. Uropathology. Philadelphia: Elsevier Saunder; 2012; 2-126.
47. Oviedo SP, Ayala AG, Ro JY. Normal Prostate Histology : Diagnostically Significant Features. In : Ro JY, Zhai QJ, Shen SS, Ayala AG. Advances in Surgical Pathology Prostate Cancer. Philadephia: Wolters Kluwer. Lippincott Williams and Wilkins; 2012. pp 143-163.
48. Gordetsky J, Epstein J. Grading of Prostatic Adenocarcinoma : Current State and Prognostic Implication. Diagnostic Pathology. Biomed Central. 2016.
49. Udoh EA, Abudu EK. Pattern Gleason Grade and Score in Prostate Cancer Histology : A Four Year Review. SAS Journal of Surgery. 2017; 3(1): 1-6.
50. White CW, Xie JH, Ventura S. Age-related Changes in the Innervation of the Prostate Gland. Organogenesis. Landesbioscience. 2013; 9 (3).
51. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. A Review of Literature. Perineural Invasion In Cancer. Cancer.2009; 115: 3379-91
52. Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signalling Pathway. Cancer. 2017; 9: 52.
53. Huang L, Fu L. Mechanism Resistance to EGFR tyrosine Kinase Inhibitor. Acta Pharmaceutica Sinica. 2015; 5 (5): 390-401.
54. Sadaoui I, Barres V, Joutei AH, Gnaoui N, Mahfoud W, Benomar H. *et al.* Prostate Adenocarcinoma : Are EGFR-targeted drugs of therapeutic relevance for castrate-resistant patients?International of Scientific and Research Publication. 2014; 4(12).
55. Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, *et al.* Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer. Human Cancer Biology. 2007;13(22)

56. Liu F, Wang JJ, You ZY, Zhang DY, Zhao Y. Radiosensitivity of Prostate Cancer Cells is Enhanced by EGFR Inhibitor C225. *Urologic Oncology ; Seminars and Original Investigation*. Elsevier. 2010; 59-66.
57. Sastroasmoro dan Ismail. *Dasar-dasar Metodologi Penelitian Klinis*. Jakarta: Sagung Seto. 2011.
58. Pepe P, Pennisi M. Gleason Score Stratification According to Age at Diagnosis in 1028 Men. *Contemporary Oncology*. 2015;19 (6).
59. Cruz JS, Passeroti CC, Reis ST, Guariero ME, Campos OD, Leite KR, *et al*. Is Age an Independent Factor for Prostate Cancer? A Paired Analysis. *Current Urology*. 2015;9;183-7
60. Rizvi MR. Review : Androgen Responsiveness in the Pathophysiology of Prostate Cancer. *International Journal of Health and Rehabilitation Sciences*. 2015; 4 (2).
61. Malley O. Epidemiologi and Etiology. In (Robinson BD, Mosquera JM, Ro JY, Divatia M) *Precision Molecular Pathology of Prostate Cancer*. Springer. 2018;13-27
62. Valdo R, Alwin M, Ferdinand T. Profil Penderita Kanker Prostat di RSUP Prof. Dr. R. D Kandou Manado periode tahun 2013-2015. *Jurnal e-Clinic*. 2016; 4 (2).
63. Mardiana N, Susilo I. Hubungan Ekspresi Her-r2/Neu, Skor Gleason dan Metastasis pada Adenokarsinoma Prostat. *Majalah Patologi Indonesia*. 2013; 22(2).
64. Heo JE, Ahn KH, Kim J, Chung BH, Lee KS. Changes in Clinical Characteristic of Patients with an Initial Diagnosis of Prostate Cancer in Korea : 10-year Trends Reported by a Tertiary Center. *Journal Korean Medical Science*. 2018; 33(6).
65. Qi M, Yang X, Zhang F, Lin T, Sun X, Li Y, *et al*. ERG Rearrangement is Associated with Prostate Cancer –Related Death in Chinese Prostate Cancer Patients. *Plos One*. 2014; 8(2).
66. Kimura T. East meets West : Ethnic Differences in Prostate Cancer Epidemiology Between East Asians and Caucasians. *Chinese Journal of Cancer*. 2012; 31(2).
67. Hammond, Hayes, Dowsett, Alfred, Hogerty, Badve, *et al*. American Society of Clinical Oncology/College of American Pathologist Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesteron Receptors In Breast Cancer. *Journal of Clinical Oncology*. 2010; 8(16); 2789-96.
68. Prichard J. Immunohistochemistry Quality Management and Regulation. In (Lin F, Prichard J) *Handbook of Practical Immunohistochemistry, frequently Asked Question*. 2<sup>nd</sup> ed. Newyork: Springer Science. 2015; 1-16
69. Lin F, Shi J. Standardization of Diagnostic Immunohostochemistry. In (Lin F, Prichard J) *Handbook of Practical Immunohistochemistry, frequently Asked Question*. 2<sup>nd</sup> ed. Newyork: Springer Science. 2015. 17-30

70. Muga S, Hernandez S, Agell L, Salido M, Juanpere N, Lorenzo M *et al.* Molecular Alteration of EGFR and PTEN in Prostate Cancer: association with High Grade and Advanced-stage Carcinoma. *Modern Pathology*. 2010; 23: 703-712.
71. Douglas DA, Zhong H, Ro JY, Oddux C, Berger AD, Pincuss MR, *et al.* Novel Mutations of Epidermal Growth Factor Receptor in Localized Prostate Cancer. *Frontiers in Bioscience*. 2006; 2818-25.
72. Fromont G, Godet J, Pires C, Yacoub M, Dore B, Irani J. Biological Significance of Perineural Invasion (PNI) In Prostate Cancer. *The Prostat. Wiley Periodical*. 2012; 542-8.
73. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM. Cancer-Related Axonogenesis and Neurogenesis in Prostate Cancer. *Human Cancer Biology. American Association for Cancer Journals*. 2008; 14(23).
74. Zareba P, Flavin R, Isikbay M, Rider JR, Gerge TA, Finn S. *et al.* Perineural Invasion and Risk of Lethal Prostate Cancer. *Cancer Epidemiology Biomarker*. 2017;26(5): 719-726.

